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Introduction
Atherosclerotic renovascular disease (ARVD) is a well-
recognized cause of arterial hypertension. However,
the role of ARVD as an important contributor to renal
failure remains a controversial issue. The original
experiments of Goldblatt et al. [1] have demonstrated
that arterial hypertension due to unilateral renal artery
stenosis (RAS) can cause bilateral renal damages.
Indeed, because of the reduced perfusion pressure
beyond the clip, the tissue of the clipped kidney is
exposed to chronic hypoxia, which leads to ischaemic
kidney injury. In the unclipped kidney however, renal
damage will progressively develop, due to the arterial
hypertension caused by the activation of the renin–
angiotensin–aldosterone system [1].
In recent years, attention to non-traditional media-
tors of ARVD such as inflammatory pathways and
microvascular events has yielded new paradigms and
avenues of research. Among other mechanisms,
reactive oxygen species (ROS) production, ischaemia/
reperfusion damage and modulation of matrix turn-
over have been proposed to promote renal failure
related to ARVD (Figure 1). The goal of this editorial
is to review the potential role of these mediators
in ARVD.
Reactive oxygen species and oxidative stress
Atherosclerosis (ATS) is now viewed as a state of
chronic inflammation and patients with ARVD may
present progressive chronic renal failure (CRF) related
to inflammatory processes that lead to ‘ischaemic
nephropathy’, which involves the extension of ATS to
the branches of the renal artery, arteriolar thickening,
tubular and glomerular atrophy, and glomerulosclero-
sis [2,3]. These are common features of the progressive
renal injury in which oxidative stress has been
proposed as playing an important role [4]. Oxidative
stress is defined as a tissue injury induced by increase in
ROS such as oxygen radicals, which can be generated
at different sites along the nephron, like the glomeruli
and segments two and three of the proximal tubule [5].
The most common oxygen radicals are superoxide
(O2 ), hydrogen peroxide (H2O2) and hydroxyl radical
(OH). O2 and OH
 are more reactive than H2O2,
which is not a radical, but which exhibits greater
membrane permeability. O2 rapidly scavenges nitric
oxide (NO) and could therefore blunt NO activity in
the renal microvasculature. Since NO inhibits oxygen
consumption, it is tempting to speculate that reduced
(scavenged) NO during ARVD elevates oxygen con-
sumption, thereby leading to reduced partial oxygen
pressure values, with consequences for endothelial—
epithelial structure and function. Since ROS are
extracellular signaling molecules, they may be signifi-
cant in mediating the actions of vasoconstrictors, such
as angiotensin II, thromboxane A2, endothelin-1,
adenosine and norepinephrine. Thus, ARVD is asso-
ciated with activation of oxidative pathways, reduction
in NO synthesis and stimulation of the renin–
angiotensin system, in humans and experimental
models. Indeed, recent studies indicate that blockade
of oxidative pathways by the superoxide mimetic,
tempol in renovascular hypertensive animals produces
a fall in arterial pressure comparable to blockade of
angiotensin receptors or administration of ACE
inhibitors [6,7]. Previous studies indicate that antiox-
idant vitamin treatment in the swine model modulates
activation of fibrogenic pathways, including nuclear
factor k-B (NF-kB), transforming growth factor-b
(TGF-b), and matrix metalloproteinases (MMPs) in
kidney tissue [8]. Taken together, these studies
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emphasize the role of shifts toward oxidative stress as a
major pathway sustaining both haemodynamic and
functional alterations of the stenotic kidney in ARVD,
amplified by chronic mechanisms that promote renal
structural injury in the normal and sick kidney [6,8–
12]. Furthermore, ROS interfere with renal oxygen
usage for tubular sodium transport and enhance
tubulo-glomerular feedback [13].
Chade et al. [13,14] have shown that increased
oxidative stress and upregulation of inflammatory
factors in ARVD are associated with marked impair-
ments of renal haemodynamics and function. The
authors demonstrated that increased abundance of
ROS initially leads to renal microvascular endothelial
dysfunction, which may precede and subsequently be
aggravated by the development of obstructive lesions in
the main renal artery. Notably, although blockade of
the oxidative stress pathway substantially attenuated
renal injury, it did not completely abolish it, suggesting
that additional pathophysiological mechanisms might
be involved. The decrease in renal blood flow and
subsequent sustained activation of the renin-
angiotensin system is probably a major trigger for
renal injury in this model [15]. Furthermore, increased
local and systemic oxidative stress can facilitate
oxidation of LDL, a cytotoxic vasoconstrictor agent
that promotes the generation of ROS and augments
functional and structural damage in the ischaemic
kidney. Reactive oxygen species may thus also play a
critical role in the development and progression of CRF
due to atherosclerotic RAS, because they are signalling
molecules of growth factors and cytokines such as
platelet-derived growth factor and TGF-b [16]. These
two factors are upregulated in the so-called ‘ischaemic’
kidney, leading to cell proliferation and extracellular
matrix (ECM) accumulation in glomerulus and inter-
stitial tissue (see further) [17].
Ischaemia/reperfusion and renal damage
One hypothesis recognized in the complex cascade
of mechanisms encountered in ARVD is represented
in the ischaemia/reperfusion phenomenon [18].
Ischaemia/reperfusion damage involves microvascular
haemodynamic changes and well-characterized oxida-
tive stress-induced tissue injury. Injury initiated by the
lack of oxygen in presence of severe RAS is augmented
by ROS once reperfusion is tempted through activa-
tion of inflammatory cascade. There is marked
congestion and hypoperfusion of the outer medulla,
which persist even though cortical blood flow improves
during reperfusion after ischaemia. The characteristic
post-ischaemic congestion worsens the relative
hypoxia, leading to prolonged cellular injury and cell
death in the predisposed tubule segments. Mechanisms
that underlie these haemodynamic alterations have
begun to surface, and they relate primarily to
endothelial cell injury [19]. A perturbation of mito-
chondrial enzyme activity and mitochondrial mem-
brane potential is found under ischaemic conditions,
causing cell apoptosis and finally cell death.
Furthermore, a low tissue PO2 is a well-established
stimulus for cell protectors such as adrenomodullin
Fig. 1. This schema summarizes current concepts linking atherosclerotic renal artery stenosis with ROS production, ischaemia/reperfusion
damage and modulation of matrix turnover to promote renal failure related to atherosclerotic renovascular disease. ROS, reactive oxygen
species; NO, nitric oxide; NF-kB, nuclear factor k-B; RAS, renal artery stenosis; HIF-1, hypoxia inducible factor-1; AM, adrenomodulin;
TEC, tubular epithelial cell; ECM, extracellular matrix; TGF-b, transforming growth factor-b; PDGF, platelet-derived growth factor;
TIMPs, tissue inhibitors of metalloproteinases; GFR, glomerular filtration rate.
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(AM) expression and hypoxia-inducible factor-1
(HIF-1) in whole kidneys and cultured renal cells
[20,21]. Sandner et al. [20] suggested that, in response
to hypoxic or ischaemic hypoxia, the rather uniform
distribution of AM in the rat kidney was changed
in keeping with oxygen gradients. In the model of
transient ischaemia, tubular damage and AM immu-
noreactivity was found predominantly in the outer
medulla. This could reflect a more rapid and longer-
lasting decrease of local PO2 during transient ischae-
mia in this zone. In support of this assumption, there is
a relatively high density of thick ascending limbs,
which are metabolically very active in this region.
Although the inner medulla is normally at the limit of
hypoxia, it apparently better tolerates transient ischae-
mic hypoxia. Indeed, tubular epithelial cells (TECs)
represent a primary target for hypoxia-elicited injury in
ischaemic conditions [21,22]. In such pathologies, non-
lethal epithelial dysfunction is typified by increased
paracellular permeability and unregulated movement
of molecules between compartments normally sepa-
rated by the tightly controlled epithelial barrier.
Hypoxia has been demonstrated to alter the expression
of a number of individual genes that contribute to TEC
injury [23]. Hypoxia-inducible factor-1 binds to the
hypoxia-response element and regulates the expression
of a number of adaptive genes coding for angiogenic
and glycolytic and other proteins (e.g. erythropoietin
and inducible nitric-oxide synthase), which support
tissue survival in hypoxia [24]. The data on AM from
cultured cells, and previous data on HIF, collectively
show that the TECs are directly sensitive to ambient
oxygen.
Renal fibrosis and modulation of matrix turnover
The poor response to revascularization observed in
ARVD has led to the speculation that synergism
between atherogenic factors and hypoperfusion distal
to the stenosis might accelerate progressive renal
disease, fibrosis, and eventual end-stage renal disease.
Renal scarring and tissue remodelling are dynamic
processes that involve both synthesis and degradation
of extracellular matrix, the balance between which
might be disrupted in several renal diseases. Hence,
matrix accumulation and fibrosis in ARVD might
result from either increased deposition or decreased
degradation of the ECM. As discussed before, several
proinflammatory and progrowth factors implicated in
renal tissue remodeling in ARVD might also be
activated in hypercholesterolaemia, a surrogate of
early ATS and an independent risk factor for renal
disease progression that might promote fibrosis and
scarring by increasing the production of fibrogenic
factors that stimulate the synthesis of ECM proteins
[8]. This is no surprise, as renal scarring is associated
with loss of microvasculature, leading to decreased
blood flow and impaired oxygenation in areas of
fibrosis. However, more recent work has suggested that
discrepancies between oxygen demand and supply can
even occur early in diseased kidneys, before visible
scarring is detected [25].
A prominent factor likely to be involved in ARVD is
oxidized LDL, which may regulate TGF-b. TGF-b
expression in ARVD is accompanied by up-regulation
and activation of its Smad effectors, underscoring
fibrogenic activity [26]. Receptor-regulated Smad-2
and Smad-3 are phosphorylated by the TGF-b
receptor, a process that is indispensable to link to
Smad-4 (cooperative Smad), and therefore initiates
recruitment of transcriptional cofactors involved in cell
proliferation and tissue growth [26]. In addition,
TGF-b is also a potent inhibitor of ECM degradation.
Indeed, it stimulates production of other profibrotic
factors such as tissue inhibitors of metalloproteinases
(TIMPs), which induce cell proliferation directly and
via inhibitory effects on MMPs [27]. Hence, the
increase in TIMP-1 and TIMP-2 protein expression
was accompanied by downregulation of the expression
and activity of MMP-2 and MMP-9, both involved in
ECM turnover. MMP-2 and MMP-9 are capable of
digesting denatured and native collagen IV, which is
often produced in the damaged kidney.
Tubular epithelial cells contribute to the progression
of renal fibrosis by undergoing an epithelial–
mesenchymal transition (EMT), leading to accumula-
tion of activated fibroblasts in the interstitium [28].
In addition to EMT, apoptosis of TECs is the principal
mechanism which leads to loss of viable TECs and
tubular atrophy [29].
Clinical consequences
A major question facing physicians and patients with
ARVD is whether the benefits of angioplasty outweigh
its risks, keeping in mind that in addition to stenotic
lesions, the degree of preexisting renal damage is a
major determinant of the clinical response to
treatment. Can the limited benefits of renal angioplasty
on blood pressure and renal function in ARVD be
explained by confounding factors? A plausible
confounder is intrinsic disease in the post-stenotic or
contralateral kidney, which cannot be altered by
renal angioplasty or may even be aggravated by the
increase in perfusion pressure once the stenosis is
relieved.
The appropriate management of patients with
ARVD requires accurate knowledge of the natural
history of this condition. Therefore, the rate of
progression of disease in the renal artery and factors
associated with increased rates of progression are
important elements to consider, when therapy or
follow-up for patients with this disease is being
planned [30]. In a recent meta-analysis, none of the
trials included showed a significant improvement in
renal function with angioplasty, despite a higher
arterial patency rate with balloon angioplasty [31].
Because of the frequency of RAS and the lack of clear
consensus on its clinical management, the National
Institute of Health has funded a prospective,
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randomized trial on the subject. This study, the
Cardiovascular Outcomes in Renal Artery Lesions
(CORAL) trial [32], is intended to determine the best
approach to RAS and which patients, if any, will
benefit from angioplasty/stent placement. The study
seeks to randomize 1080 patients either to angioplasty/
stent placement and optimal medical therapy, or to
optimal medical therapy alone. The endpoint of this
trial is a composite outcome related both to cardio-
vascular events, hospitalization, and renal dysfunction
over a 5 year period. The CORAL trial will add
considerably to information that until now has been
determined mainly by retrospective observational
reports or registries. Furthermore, some authors
speculate that medically controlled patients after
stenting fare worse than those with uncontrolled
blood pressure because of underperfusion related to
distal embolization worsened by antihypertensive
therapy. The CORAL trial includes a distal protection
device to minimize such hazards for those undergoing
stenting. These observations argue further that the
decision to undertake renal revascularization continues
to be complex and highly dependent upon comorbid
risks for each patient. Its place might be indicated in
patients with high serum creatinine concentrations and
bilateral atherosclerotic RAS, those with tight athero-
sclerotic RAS in a single kidney, and particularly those
with flash pulmonary oedema.
Conclusions
The life expectancy of patients with atheromatous
disease affecting the renal arteries is drastically
reduced, even after stenting of the stenotic lesion [33].
It is, therefore, a difficult task to balance the risks and
costs against the expected benefits. Research designed
to better understand the underlying pathology of
ARVD has already yielded information that has
expanded our focus to encompass inflammation and
fibrosis among other biological processes. Continued
efforts may result in further challenges to some
long-held notions and contribute to improved diag-
nostic and treatment tools. By using clinical and
paraclinical tools in combination, better risk profiles
may emerge to provide prognostic information, direct
therapy, gauge efficacy of interventions, and develop
new medications. In 1998, Caps et al. [34] identified
several classical risk factors for the progression of renal
artery disease. Among them, a systolic blood pressure
>160mmHg, the presence of diabetes mellitus and a
high grade ipsilateral or contralateral RAS were
found to yield a very high risk of disease progression.
In the future, new parameters linked to inflammation
and ATS might further improve our assessment of the
renal risk of patients with ARVD. However, while
waiting for these new prognostic factors to be
developed, aggressive blood pressure control in
patients with ARVD is a critical element to protect
renal function. Moreover, an increased emphasis
should be put on other risk factors such as
dyslipidaemia, smoking and diabetes, which also
increase the risk of renal artery disease progression in
patients with ARVD.
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